<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04963777</url>
  </required_header>
  <id_info>
    <org_study_id>REB21-0852</org_study_id>
    <nct_id>NCT04963777</nct_id>
  </id_info>
  <brief_title>Prebiotics in Newly Diagnosed Type 1 Diabetes</brief_title>
  <official_title>Effect of Prebiotic Fibre on Glycemic Control, Gut Microbiota, and Intestinal Permeability in Newly Diagnosed (&lt;12 Months) Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Calgary</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Calgary</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evidence suggests that prebiotic fibre can correct dysbiosis, reduce intestinal permeability&#xD;
      and improve glycemic control. The investigators hypothesize that microbial changes induced by&#xD;
      prebiotics contribute to gut and endocrine adaptations that reduce glucose fluctuations,&#xD;
      including less hyper- and hypoglycemia in type 1 diabetes (T1D). The primary objective is to&#xD;
      compare the change in frequency of hypoglycemia from baseline to 6 months in n=144 newly&#xD;
      diagnosed (&lt;12 months) individuals with T1D treated with a 6-month course of prebiotic or&#xD;
      placebo as an adjunct to insulin. Secondary objectives will be aimed at understanding the&#xD;
      mechanisms by which the prebiotics could affect glycemic control.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators hypothesize that, as an adjunct to insulin, prebiotic supplementation will&#xD;
      reduce the frequency of hypoglycemia and improve glycemic variability that is accompanied by&#xD;
      enhanced serum C-peptide levels, a reduction in intestinal permeability and systemic&#xD;
      inflammation, and altered gut microbiota.&#xD;
&#xD;
      Primary Objective To compare the change in frequency of hypoglycemia from baseline to 6&#xD;
      months in newly diagnosed (&lt;12 months) individuals with T1D treated with a 6-month course of&#xD;
      prebiotic or placebo as an adjunct to insulin.&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
        1. To determine the change in glycemic variability and glycemic control using Continuous&#xD;
           Glucose Monitor (CGM) metrics including: percentage change in Time In-, Below-, and&#xD;
           Above-Range (i.e. TIR, TBR, and TAR) and A1C from baseline to 6 months in those treated&#xD;
           with prebiotic or placebo.&#xD;
&#xD;
        2. To compare the change in stimulated C-peptide and pro-insulin from baseline to 6 months.&#xD;
&#xD;
        3. To determine the change in IP from baseline to 6 months.&#xD;
&#xD;
        4. To determine the change in serum inflammatory markers (IL-6, IFN-gamma, TNF, C-reactive&#xD;
           protein, and IL-10).&#xD;
&#xD;
        5. To examine quality of life (QOL) and fear of hypoglycemia ratings, and adverse reactions&#xD;
           (severe hypoglycemia, diabetic ketoacidosis, side effects).&#xD;
&#xD;
        6. To examine prebiotic-induced changes in gut microbiota composition and function (shotgun&#xD;
           sequencing) and their metabolic by-products (fecal and serum metabolomics).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2026</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Multi-centre placebo controlled double-blind randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>The prebiotic and placebo are both white powders with similar sweet taste and dissolve in water.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in frequency of hypoglycemia</measure>
    <time_frame>6 months</time_frame>
    <description>Blood glucose &lt;3.9 mmol/L from continuous glucose monitor data</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in glycemic control</measure>
    <time_frame>6 months</time_frame>
    <description>Glycated hemoglobin (A1C)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in stimulated C-peptide</measure>
    <time_frame>6 months</time_frame>
    <description>Serum collected during a mixed meal tolerance test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Intestinal permeability</measure>
    <time_frame>6 months</time_frame>
    <description>Urinary lactulose/mannitol test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inflammatory marker IL-6</measure>
    <time_frame>6 months</time_frame>
    <description>Serum IL-6</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in quality of life</measure>
    <time_frame>6 months</time_frame>
    <description>Diabetes-specific quality of life survey</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dietary intake</measure>
    <time_frame>6 months</time_frame>
    <description>24 hour dietary recall (energy intake, fat intake, carbohydrate intake, protein intake, fiber intake)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiota composition</measure>
    <time_frame>6 months</time_frame>
    <description>Fecal microbiota taxonomy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in gut microbiota function</measure>
    <time_frame>6 months</time_frame>
    <description>Fecal microbiota shotgun sequencing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum metabolite concentration</measure>
    <time_frame>6 months</time_frame>
    <description>Serum LC-Qtof-Mass Spec metabolomics</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">144</enrollment>
  <condition>Type 1 Diabetes</condition>
  <arm_group>
    <arm_group_label>Prebiotic</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Oligofructose-enriched inulin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Maltodextrin</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Prebiotic</intervention_name>
    <description>Chicory root derived inulin-type fructan (8 g/day for ages 8-13 years; 16 g/day for ages ≥14 years)</description>
    <arm_group_label>Prebiotic</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Maltodextrin (isocaloric; 3.3 g/day for ages 8-13 years; 6.6 g/day for ≥14 years)</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosed with type 1 diabetes (based on Diabetes Canada 2018 Clinical Practice&#xD;
             Guideline diagnostic criteria) in the previous 12 months.&#xD;
&#xD;
          -  Age 8 years and above (as per our pilot trial and able to complete the required&#xD;
             tests).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Regular use of medications or supplements that could affect gut microbiota (examples:&#xD;
             antibiotics, probiotic or prebiotic supplements, laxatives) within 3 months prior to&#xD;
             enrollment.&#xD;
&#xD;
          -  Previous intestinal surgery.&#xD;
&#xD;
          -  Another chronic medical condition that could affect gut microbiota or intestinal&#xD;
             permeability (examples: Crohn's disease, Celiac disease, colitis, irritable bowel&#xD;
             syndrome)&#xD;
&#xD;
          -  Presence of active infection, pregnancy or lactation.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Raylene A Reimer, PhD, RD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Calgary</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Raylene A Reimer, PhD, RD</last_name>
    <phone>403-220-8218</phone>
    <email>reimer@ucalgary.ca</email>
  </overall_contact>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 12, 2021</study_first_submitted>
  <study_first_submitted_qc>July 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 15, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Calgary</investigator_affiliation>
    <investigator_full_name>Dr. Raylene Reimer</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Gut microbiota</keyword>
  <keyword>Glycemic control</keyword>
  <keyword>Prebiotic</keyword>
  <keyword>Oligofructose-enriched inulin</keyword>
  <keyword>Hypoglycemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

